What Briumvi treats.
- Relapsing forms of multiple sclerosis (RRMS, SPMS, CIS)
The mechanism.
Briumvi (ublituximab) is a glycoengineered anti-CD20 antibody that depletes B cells implicated in MS. Compared to earlier B-cell therapies, Briumvi was designed for enhanced cell-killing efficiency, allowing for shorter infusion times after the initial dose.
Your Briumvi infusion experience.
Initial Briumvi infusion is 4 hours, the second (two weeks later) is 1 hour, and all maintenance infusions every 6 months are 1 hour. This compact schedule is one of Briumvi’s key advantages over older B-cell therapies. Pre-medications are required.
Insurance & out-of-pocket cost.
Briumvi is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.